JP Morgan Call 210 PGR 17.01.2025/ DE000JB9Y9F6 /
2024-08-01 9:58:12 AM | Chg.-0.24 | Bid1:24:59 PM | Ask1:24:59 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
1.98EUR | -10.81% | 2.27 Bid Size: 2,000 |
2.37 Ask Size: 2,000 |
Progressive Corporat... | 210.00 USD | 2025-01-17 | Call |
GlobeNewswire
06-25
argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 P...
GlobeNewswire
06-24
Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Tri...
GlobeNewswire
06-24
4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geo...
GlobeNewswire
06-24
Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-4...
GlobeNewswire
06-13
Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Progr...
GlobeNewswire
06-12
Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo...
GlobeNewswire
06-12
Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japa...
GlobeNewswire
06-11
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D ...
GlobeNewswire
06-11
Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b...
GlobeNewswire
06-11
FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclero...